Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 28Genitourinary 26Gastrointestinal 26Thoracic 17Gynecologic 14CNS 7Head & Neck 6Lymphoid 5Sarcoma 4Other hematologic neoplasm 4Dermatologic 4Tumor-Agnostic 2Other 2Endocrine 2Plasma cell 1Other neoplasm 1NET 1Classical hematology 1

Conditions

Smoldering Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1

Interventions

Dexamethasone 374Lenalidomide 206Bortezomib 201Cyclophosphamide 178Melphalan 135Calcium Dobesilate 120daratumumab 107pomalidomide 74carfilzomib 74fludarabine phosphate 71Peripheral Blood Stem Cell Transplantation 66Thalidomide 57Filgrastim 57Mycophenolic Acid 56Busulfan 55Tacrolimus 48Granulocyte Colony-Stimulating Factor 47ixazomib 45fludarabine 45Whole-Body Irradiation 44dexamethasone acetate 36Cyclosporine 35isatuximab 34Etoposide 34Antilymphocyte Serum 32dexamethasone 21-phosphate 30elotuzumab 28auricularum 27Prednisone 27plerixafor 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Metformin × Plasma cell × Clear all
NCT04850846 2026-02-09

Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
60 enrolled 10 charts
Plasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance

Data powered by HemOnc (CC BY 4.0) Colophon âš¡